Café

© 2026 Longbridge｜Terms of Service Privacy Policy

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | CERO Stock News

StockTitan

Mar 30, 2026 at 04:15 AM

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | CERO Stock News

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | CERO Stock News

Login to unlock94characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

Sep 8, 2026 at 10:49 AMSingapore shares fall on Tuesday amid regional slump; STI down 0.4%
Sep 8, 2026 at 09:12 AMU.S. stocks usually stumble after Fed hikes, but these markets tend to climb, says Citi
Apr 20, 2026 at 06:34 PMEli Lilly Announces $7 Billion Acquisition of Kelonia: Pioneering the 'In Vivo CAR-T' Frontier and Leading Gene Therapy …
Apr 16, 2026 at 11:12 AMUS Stocks Hit New Highs, Retail Investors Miss Out en masse: Tom Lee Says Next Rally Will Be Led by Them
Apr 7, 2026 at 10:32 PMReminder: Key events to watch intraday (all times Beijing Time)

Related Stocks

CERo Therapeutics

USCERO

iShares Biotechnology ETF

USIBB

Direxion S&P Biotech Bull 3X

USLABU

LongbridgeAI